• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Channel Therapeutics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    5/1/25 5:05:54 PM ET
    $CHRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CHRO alert in real time by email
    false 0001919246 0001919246 2025-05-01 2025-05-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 1, 2025

     

    Channel Therapeutics Corporation

    (Exact name of registrant as specified in its charter)

     

    Nevada   001-41964   86-3335449
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    4400 Route 9 South, Suite 1000

    Freehold, NJ

      07728
    (Address of registrant’s principal executive office)   (Zip code)

     

    Registrant’s telephone number, including area code: (877) 265-8266

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   CHRO   The NYSE American LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 7.01.Regulation FD Disclosure.

     

    In accordance with Sections 401(h) and 610(b) of the NYSE American LLC Company Guide, a company listed on the NYSE American LLC that receives an audit opinion that contains a going concern emphasis or qualification must make a contemporaneous public announcement through the news media disclosing the receipt of such qualified opinion. The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission on March 27, 2025, contains an audit opinion that contains a going concern emphasis or qualification.

     

    On May 1, 2025, Channel Therapeutics Corporation (the “Company”) issued the required press release. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein. The announcement does not represent any change or amendment to the Company’s audited financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2024.

     

    The information furnished pursuant to this Item 7.01 (including Exhibit 99.1 hereto), shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

     

    Item 9.01. Financial Statements and Exhibits.

     

      (d) Exhibits.

     

    The following documents are filed as exhibits to this Current Report on Form 8-K:

     

    Exhibit No.   Description
    99.1   Press Release dated May 1, 2025
    Exhibit 104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: May 1, 2025 Channel Therapeutics Corporation
         
      By: /s/ Francis Knuettel II
        Name: Francis Knuettel II
        Title: Chief Executive Officer and Chief Financial Officer

     

     

    Get the next $CHRO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CHRO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CHRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Friedberg Ezra M converted options into 80,000 shares (SEC Form 4)

      4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

      7/3/25 9:05:54 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Francis Knuettel Ii converted options into 10,000 shares (SEC Form 4)

      4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

      7/3/25 9:04:18 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Davis Todd C converted options into 1,500,000 shares (SEC Form 4)

      4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

      7/3/25 9:02:33 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Malamut Richard bought $9,825 worth of shares (10,400 units at $0.94) (SEC Form 4)

      4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

      9/16/24 4:56:55 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO, Pres., CFO, Treas & Secty Francis Knuettel Ii bought $5,044 worth of shares (5,200 units at $0.97) (SEC Form 4)

      4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

      9/16/24 4:55:23 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO, Pres., CFO, Treas & Secty Francis Knuettel Ii bought $10,955 worth of shares (12,000 units at $0.91) (SEC Form 4)

      4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

      9/12/24 5:35:41 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

      The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Me

      7/2/25 7:00:00 AM ET
      $CHRO
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement

      FREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), an emerging leader in the development of non-opioid pain treatment therapeutics, today announced a 10-for-one reverse split (the "Reverse Stock Split") of the Company's common stock (the "Common Stock"). The Reverse Stock Split is intended to increase the market price per share of the Company's Common Stock and help the Company satisfy the initial listing requirements of the NYSE American (the "NYSE American") in connection with the anticipated closing of the previously announced merger of CHRO Merger Sub, Inc., a wholly owned subsidiary of the Company, with and in

      6/27/25 9:15:00 AM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using its NaV1.7 Inhibitor in Multiple Preclinical In Vivo Models

      FREEHOLD, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has achieved its predefined endpoints in two pre-clinical animal models of the Company's eye drop formulations ("CT2000") for the treatment of both acute ocular pain as well as chronic ocular surface pain commonly associated with dry eye disease. "We are very pleased with the results of these animal efficacy studies, which adds to the Depot formulation study results announced in December 2024, demonstrating a viable path forward in treating both post-surgical pain and ch

      5/14/25 8:00:00 AM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Channel Therapeutics Corporation

      SCHEDULE 13D/A - Pelthos Therapeutics Inc. (0001919246) (Subject)

      7/3/25 9:07:22 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13D filed by Channel Therapeutics Corporation

      SCHEDULE 13D - Pelthos Therapeutics Inc. (0001919246) (Subject)

      7/3/25 4:05:07 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Channel Therapeutics Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)

      7/2/25 5:22:26 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Chromocell Therapeutics Corporation

      SC 13G/A - Chromocell Therapeutics Corp (0001919246) (Subject)

      11/13/24 4:05:24 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Chromocell Therapeutics Corporation

      SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

      3/4/24 4:07:02 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Chromocell Therapeutics Corporation

      SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

      3/1/24 5:19:37 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

      The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Me

      7/2/25 7:00:00 AM ET
      $CHRO
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations